Correction: HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide
Gespeichert in:
| Veröffentlicht in: | Oncotarget 2023-09, Vol.14 (1), p.837-838 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 838 |
|---|---|
| container_issue | 1 |
| container_start_page | 837 |
| container_title | Oncotarget |
| container_volume | 14 |
| creator | Canella, Alessandro Nieves, Hector Cordero Sborov, Douglas W. Cascione, Luciano Radomska, Hanna S. Smith, Emily Stiff, Andrew Consiglio, Jessica Caserta, Enrico Rizzotto, Lara Zanesi, Nicola Stefano, Volinia Kaur, Balveen Mo, Xiaokui Byrd, John C. Efebera, Yvonne A. Hofmeister, Craig C. Pichiorri, Flavia |
| description | |
| doi_str_mv | 10.18632/oncotarget.28515 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10519243</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2868673017</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1745-50013febee866839953adc3dba9db12af20352fb646571ddd767d10e9e6e16193</originalsourceid><addsrcrecordid>eNpVkUtLJDEUhYM4qDj9A9xl6aY071RmI035BGFgmFmHVOVWG6lK2qRa1F9vacuod3MvnMO5HD6Ejig5obXi7DTFLk0ur2A6YbWkcgcdUCNMxaTku1_ufbQo5Z7MI4WumdlD-1xrobniB2jVpJyhm0KKv_D1-bLBId6FNkwp4-WfSjDsocvgChTcnAuB4WmdoZTZj130uEAsYQovszw-w5BGhzsYhoKnhAeIbgg-jcHDT_Sjd0OBxcc-RP8uL_4219Xt76ubZnlbdVQLWUlCKO-hBaiVqrkxkjvfcd8641vKXM8Il6xvlVBSU--9VtpTAgYUUEUNP0Rn29z1ph3BdxCn7Aa7zmF0-dkmF-x3JYY7u0qPlhJJDRN8Tjj-SMjpYQNlsmMob51chLQpltWqVpoTqmcr3Vq7nErJ0P__Q4l9h2Q_Idl3SPwVsR-HQw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2868673017</pqid></control><display><type>article</type><title>Correction: HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>PubMed Central</source><source>Free E- Journals</source><creator>Canella, Alessandro ; Nieves, Hector Cordero ; Sborov, Douglas W. ; Cascione, Luciano ; Radomska, Hanna S. ; Smith, Emily ; Stiff, Andrew ; Consiglio, Jessica ; Caserta, Enrico ; Rizzotto, Lara ; Zanesi, Nicola ; Stefano, Volinia ; Kaur, Balveen ; Mo, Xiaokui ; Byrd, John C. ; Efebera, Yvonne A. ; Hofmeister, Craig C. ; Pichiorri, Flavia</creator><creatorcontrib>Canella, Alessandro ; Nieves, Hector Cordero ; Sborov, Douglas W. ; Cascione, Luciano ; Radomska, Hanna S. ; Smith, Emily ; Stiff, Andrew ; Consiglio, Jessica ; Caserta, Enrico ; Rizzotto, Lara ; Zanesi, Nicola ; Stefano, Volinia ; Kaur, Balveen ; Mo, Xiaokui ; Byrd, John C. ; Efebera, Yvonne A. ; Hofmeister, Craig C. ; Pichiorri, Flavia</creatorcontrib><identifier>ISSN: 1949-2553</identifier><identifier>EISSN: 1949-2553</identifier><identifier>DOI: 10.18632/oncotarget.28515</identifier><identifier>PMID: 37747363</identifier><language>eng</language><publisher>Impact Journals LLC</publisher><ispartof>Oncotarget, 2023-09, Vol.14 (1), p.837-838</ispartof><rights>Copyright: © 2023 Canella et al.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10519243/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10519243/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids></links><search><creatorcontrib>Canella, Alessandro</creatorcontrib><creatorcontrib>Nieves, Hector Cordero</creatorcontrib><creatorcontrib>Sborov, Douglas W.</creatorcontrib><creatorcontrib>Cascione, Luciano</creatorcontrib><creatorcontrib>Radomska, Hanna S.</creatorcontrib><creatorcontrib>Smith, Emily</creatorcontrib><creatorcontrib>Stiff, Andrew</creatorcontrib><creatorcontrib>Consiglio, Jessica</creatorcontrib><creatorcontrib>Caserta, Enrico</creatorcontrib><creatorcontrib>Rizzotto, Lara</creatorcontrib><creatorcontrib>Zanesi, Nicola</creatorcontrib><creatorcontrib>Stefano, Volinia</creatorcontrib><creatorcontrib>Kaur, Balveen</creatorcontrib><creatorcontrib>Mo, Xiaokui</creatorcontrib><creatorcontrib>Byrd, John C.</creatorcontrib><creatorcontrib>Efebera, Yvonne A.</creatorcontrib><creatorcontrib>Hofmeister, Craig C.</creatorcontrib><creatorcontrib>Pichiorri, Flavia</creatorcontrib><title>Correction: HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide</title><title>Oncotarget</title><issn>1949-2553</issn><issn>1949-2553</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNpVkUtLJDEUhYM4qDj9A9xl6aY071RmI035BGFgmFmHVOVWG6lK2qRa1F9vacuod3MvnMO5HD6Ejig5obXi7DTFLk0ur2A6YbWkcgcdUCNMxaTku1_ufbQo5Z7MI4WumdlD-1xrobniB2jVpJyhm0KKv_D1-bLBId6FNkwp4-WfSjDsocvgChTcnAuB4WmdoZTZj130uEAsYQovszw-w5BGhzsYhoKnhAeIbgg-jcHDT_Sjd0OBxcc-RP8uL_4219Xt76ubZnlbdVQLWUlCKO-hBaiVqrkxkjvfcd8641vKXM8Il6xvlVBSU--9VtpTAgYUUEUNP0Rn29z1ph3BdxCn7Aa7zmF0-dkmF-x3JYY7u0qPlhJJDRN8Tjj-SMjpYQNlsmMob51chLQpltWqVpoTqmcr3Vq7nErJ0P__Q4l9h2Q_Idl3SPwVsR-HQw</recordid><startdate>20230925</startdate><enddate>20230925</enddate><creator>Canella, Alessandro</creator><creator>Nieves, Hector Cordero</creator><creator>Sborov, Douglas W.</creator><creator>Cascione, Luciano</creator><creator>Radomska, Hanna S.</creator><creator>Smith, Emily</creator><creator>Stiff, Andrew</creator><creator>Consiglio, Jessica</creator><creator>Caserta, Enrico</creator><creator>Rizzotto, Lara</creator><creator>Zanesi, Nicola</creator><creator>Stefano, Volinia</creator><creator>Kaur, Balveen</creator><creator>Mo, Xiaokui</creator><creator>Byrd, John C.</creator><creator>Efebera, Yvonne A.</creator><creator>Hofmeister, Craig C.</creator><creator>Pichiorri, Flavia</creator><general>Impact Journals LLC</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20230925</creationdate><title>Correction: HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide</title><author>Canella, Alessandro ; Nieves, Hector Cordero ; Sborov, Douglas W. ; Cascione, Luciano ; Radomska, Hanna S. ; Smith, Emily ; Stiff, Andrew ; Consiglio, Jessica ; Caserta, Enrico ; Rizzotto, Lara ; Zanesi, Nicola ; Stefano, Volinia ; Kaur, Balveen ; Mo, Xiaokui ; Byrd, John C. ; Efebera, Yvonne A. ; Hofmeister, Craig C. ; Pichiorri, Flavia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1745-50013febee866839953adc3dba9db12af20352fb646571ddd767d10e9e6e16193</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Canella, Alessandro</creatorcontrib><creatorcontrib>Nieves, Hector Cordero</creatorcontrib><creatorcontrib>Sborov, Douglas W.</creatorcontrib><creatorcontrib>Cascione, Luciano</creatorcontrib><creatorcontrib>Radomska, Hanna S.</creatorcontrib><creatorcontrib>Smith, Emily</creatorcontrib><creatorcontrib>Stiff, Andrew</creatorcontrib><creatorcontrib>Consiglio, Jessica</creatorcontrib><creatorcontrib>Caserta, Enrico</creatorcontrib><creatorcontrib>Rizzotto, Lara</creatorcontrib><creatorcontrib>Zanesi, Nicola</creatorcontrib><creatorcontrib>Stefano, Volinia</creatorcontrib><creatorcontrib>Kaur, Balveen</creatorcontrib><creatorcontrib>Mo, Xiaokui</creatorcontrib><creatorcontrib>Byrd, John C.</creatorcontrib><creatorcontrib>Efebera, Yvonne A.</creatorcontrib><creatorcontrib>Hofmeister, Craig C.</creatorcontrib><creatorcontrib>Pichiorri, Flavia</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oncotarget</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Canella, Alessandro</au><au>Nieves, Hector Cordero</au><au>Sborov, Douglas W.</au><au>Cascione, Luciano</au><au>Radomska, Hanna S.</au><au>Smith, Emily</au><au>Stiff, Andrew</au><au>Consiglio, Jessica</au><au>Caserta, Enrico</au><au>Rizzotto, Lara</au><au>Zanesi, Nicola</au><au>Stefano, Volinia</au><au>Kaur, Balveen</au><au>Mo, Xiaokui</au><au>Byrd, John C.</au><au>Efebera, Yvonne A.</au><au>Hofmeister, Craig C.</au><au>Pichiorri, Flavia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Correction: HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide</atitle><jtitle>Oncotarget</jtitle><date>2023-09-25</date><risdate>2023</risdate><volume>14</volume><issue>1</issue><spage>837</spage><epage>838</epage><pages>837-838</pages><issn>1949-2553</issn><eissn>1949-2553</eissn><pub>Impact Journals LLC</pub><pmid>37747363</pmid><doi>10.18632/oncotarget.28515</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1949-2553 |
| ispartof | Oncotarget, 2023-09, Vol.14 (1), p.837-838 |
| issn | 1949-2553 1949-2553 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10519243 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; PubMed Central; Free E- Journals |
| title | Correction: HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T20%3A10%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Correction:%20HDAC%20inhibitor%20AR-42%20decreases%20CD44%20expression%20and%20sensitizes%20myeloma%20cells%20to%20lenalidomide&rft.jtitle=Oncotarget&rft.au=Canella,%20Alessandro&rft.date=2023-09-25&rft.volume=14&rft.issue=1&rft.spage=837&rft.epage=838&rft.pages=837-838&rft.issn=1949-2553&rft.eissn=1949-2553&rft_id=info:doi/10.18632/oncotarget.28515&rft_dat=%3Cproquest_pubme%3E2868673017%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2868673017&rft_id=info:pmid/37747363&rfr_iscdi=true |